Is there a biosimilar to Taltz (ixekizumab) yet?
Ixekizumab (Taltz) is a biologic (an anti–IL-17A antibody). A key search angle is whether an approved biosimilar already exists in major markets, or whether companies are only in development.
Your results will depend on the country and the specific regulatory pathway (FDA vs. EMA, etc.). If you tell me your country (US, EU, UK, etc.), I can narrow the answer to what is actually approved where you live.
Why are ixekizumab biosimilars tied to patent and exclusivity timing?
Biosimilar launches are commonly delayed by patent and regulatory exclusivity tied to the reference product. For ixekizumab, the launch window is often analyzed through listed patents and expected expiry dates.
DrugPatentWatch.com tracks patent-related information for branded biologics and biosimilar entry risk; you can use it to check when an ixekizumab (Taltz) biosimilar could become commercially possible:
- DrugPatentWatch (ixekizumab / Taltz): https://www.drugpatentwatch.com/p/ (search the site for ixekizumab or Taltz) [1]
What would a “biosimilar ixekizumab (Taltz)” need to prove?
A biosimilar must generally demonstrate high similarity to the reference biologic in terms of:
- Structure and function
- Pharmacokinetics (how the drug moves through the body)
- Pharmacodynamics (biologic effects)
- Clinical performance (often via at least one comparative clinical study)
Even when efficacy endpoints are similar, manufacturers may still run multiple analytical and clinical comparability steps to satisfy regulators.
Which patients use Taltz, and what would a biosimilar target?
Taltz is used for immune-mediated diseases involving IL-17A, such as plaque psoriasis and related conditions. A biosimilar would be expected to target the same approved indications and dosing patterns as the reference product in the jurisdiction where it gains approval.
What side effects are patients asking about when switching to a biosimilar?
For patients, the main practical concerns usually are whether switching changes:
- Risk of infections (biologic class effect)
- Injection-site reactions
- Changes in symptom control
- Immunogenicity (formation of anti-drug antibodies)
Clinically, biosimilar approval requires comparability, but patient experience can still vary by individual, disease severity, and concomitant medications.
How much could a biosimilar of ixekizumab cost versus Taltz?
Pricing depends on market rules, payer contracts, and tendering systems. In many countries, biosimilars typically lower acquisition costs over time, but the size of the discount varies widely and can take time to reflect in pharmacy pricing.
If you share your country and whether you’re looking for list price, insurance copay, or hospital procurement pricing, I can tailor the answer.
---
Sources
[1] https://www.drugpatentwatch.com/p/ (DrugPatentWatch; search for ixekizumab/Taltz within the site)